Results 61 to 70 of about 54,679 (264)

Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial

Nature Medicine, 2023
The combination of neoadjuvant nivolumab, ipilimumab and chemotherapy showed promising efficacy in patients with resectable non-small cell lung cancer, with higher tumor immune cell infiltration and tertiary lymphoid structures after treatment compared ...
T. Cascone, C. Leung, A. Weissferdt, A. Pataer, B. Carter, M. Godoy, Hope A. Feldman, W. William, Y. Xi, Sreyashi Basu, J. Sun, S. Yadav, F. R. Rojas Alvarez, Younghee Lee, Aditya K Mishra, Lili Chen, M. Pradhan, Haiping Guo, Ansam Sinjab, N. Zhou, M. Negrão, X. Le, C. Gay, A. Tsao, L. Byers, M. Altan, B. Glisson, F. Fossella, Y. Elamin, G. Blumenschein, Jianjun Zhang, F. Skoulidis, Jia Wu, R. Mehran, D. Rice, G. Walsh, W. Hofstetter, R. Rajaram, M. Antonoff, J. Fujimoto, L. Solis, E. Parra, C. Haymaker, I. Wistuba, S. Swisher, A. Vaporciyan, Heather Y. Lin, Jing Wang, D. Gibbons, J. Jack Lee, N. Ajami, J. Wargo, J. Allison, Padmanee Sharma, H. Kadara, J. Heymach, B. Sepesi   +56 more
semanticscholar   +1 more source

Immune Checkpoint Inhibitor–Related Myositis and Associated Triad Overlap Syndrome

Arthritis Care &Research, EarlyView.
Objective Immune checkpoint inhibitor (ICI) myositis is a rare but a highly morbid condition, particularly with the ICI myositis triad syndrome of myositis, myocarditis, and myasthenia gravis. We report the clinical characteristics of ICI myositis and all‐cause mortality in these patients.
Selene Rubino, Grant W. Cannon, Brian C. Sauer, Jorge Rojas, Gregory J. Stoddard, Gary A. Kunkel, Jessica A. Walsh, Bryant R. England, Joshua F. Baker, Tawnie J. Braaten   +9 more
wiley   +1 more source

Successful Treatment of Nivolumab-Resistant Multiple In-Transit Melanomas with Ipilimumab and Topical Imiquimod

Case Reports in Oncology, 2018
Simultaneous or sequential, planned administration of ipilimumab could significantly enhance the antitumor effects of nivolumab in advanced melanoma patients.
Taku Fujimura, Yumi Kambayashi, Yota Sato, Kayo Tanita, Sadanori Furudate, Akira Tsukada, Hisayuki Tono, Akira Hashimoto, Setsuya Aiba   +8 more
doaj   +1 more source

European Medicines Agency extension of indication to include the combination immunotherapy cancer drug treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) for adults with intermediate/poor-risk advanced renal cell carcinoma

ESMO Open, 2020
On the 15 November 2018, the Committee for Medicinal Products for Human Use adopted an extension to an existing indication for the use of nivolumab (Opdivo) in combination with ipilimumab (Yervoy) for the first-line treatment of adult patients with ...
Jorge Camarero, Filip Josephson, Maja Sommerfelt Grønvold, Nikolaos Zafiropoulos, Sahra Ali, Paula van Hennik, Christian Syvertsen, Bjorn Oddvar Strøm, Mats Ökvist, Brigitte Keller-Stanislawski, Elias Pean, Silvy da Rocha Dias, Franscesco Pignatti   +12 more
doaj   +1 more source

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer

Frontiers in Pharmacology, 2021
Objective: This study evaluated the cost-effectiveness of nivolumab plus ipilimumab vs. chemotherapy in the first-line setting for patients with advanced non-small-cell lung cancer (NSCLC) from the US payer perspective.Materials and methods: A Markov ...
Xiaomin Wan, Xiaohui Zeng, Liubao Peng, Ye Peng, Qiao Liu, Lidan Yi, Xia Luo, Qijian Deng, Qijian Deng, Chongqing Tan   +9 more
doaj   +1 more source

Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): results from a double-blind, randomised, phase 3 trial

The Lancet, 2023
Summary Background Effective adjuvant therapy for patients with resected localised renal cell carcinoma represents an unmet need, with surveillance a current standard of care.
R. Motzer, P. Russo, V. Grünwald, Y. Tomita, B. Żurawski, Omi Parikh, S. Buti, P. Barthélémy, J. Goh, Dingwei Ye, A. Lingua, J. Lattouf, L. Albiges, S. George, B. Shuch, J. Sosman, M. Staehler, S. V. Estévez, B. Simsek, Julia Spiridigliozzi, A. Chudnovsky, A. Bex   +21 more
semanticscholar   +1 more source

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

Advanced Science, EarlyView.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun, Haochen Yang, Qing Xu, Xingya Li, Jinxing Lou, Jianchun Duan, Jiachen Xu, Zhuqing Liu, Yong Xia, Zhicai Lin, Linlin Li, Dan Sun, Jiaguo Li, Tao Liu, Jun Guo, Wenfeng Xu, Weimin Zhu, Yi Liu, Boyang Sun, Jia Zhong, Lijie Rong, Qijun Qian, Chenqi Xu, Jie Wang   +23 more
wiley   +1 more source

Dose escalation phase 1 study of radiotherapy in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody ipilimumab in patients with metastatic melanoma

Journal for ImmunoTherapy of Cancer, 2020
Background A synergy between radiotherapy and anti-cytotoxic-T-lymphocyte-associated antigen 4 (anti-CTLA-4) monoclonal antibody has been demonstrated preclinically.
Caroline Robert, Christine Mateus, Christophe Massard, Roger Sun, Eric Deutsch, Lydie Cassard, Rastilav Bahleda, Severine Roy, Emilie Routier, Nathalie Chaput-Gras, Caroline Caramella, Emilie Lanoy, Alicia Larive, Yun Gan Tao, Dominique Schwob, Nathalie Ibrahim, Rita Maria Khoury Abboud, J -C Soria   +17 more
doaj   +1 more source

Genome‐Wide CRISPR Screen Identifies a microRNA Orchestrating Pleiotropic Resistance to Targeted Therapy and T Cell Immunity in Melanoma

Advanced Science, EarlyView.
A genome‐wide microRNA CRISPR screen identifies miR‐18a as a master regulator of cross‐resistance in melanoma. Loss of miR‐18a activates the AJUBA–YAP/Hippo axis to confer BRAFi resistance and enhances THBS1–CD47 interaction to impair CD8+ T cell immunity. hnRNP A1 is identified as an upstream regulator of miR‐18a processing.
Zhao Wang, Haotian Liu, Xueqi Wang, Jianjin Teng, Zihan Zheng, Jingya Zhang, Wanyi Xiao, Qian Liang, Jiaxin Li, Xiaomeng Jia, Xin Feng, Hongzhang Cui, Menghan Luo, Tielong Yang, Liuxing Wu, Ke Zhao, Weilong Yang, Mulin Jun Li, Dandan Huang, Jilong Yang   +19 more
wiley   +1 more source

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

Clinical Cancer Research, 2023
Purpose: In the phase III CheckMate 238 study, adjuvant nivolumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival versus ipilimumab in patients with resected stage IIIB–C or stage IV melanoma, with benefit ...
J. Larkin, M. Del Vecchio, M. Mandalà, H. Gogas, A. Arance, S. Dalle, C. Cowey, M. Schenker, J. Grob, V. Chiarion-Sileni, I. Márquez-Rodas, M. Butler, Anna Maria Di Giacomo, M. Middleton, J. Lutzky, L. de la Cruz-Merino, P. Arenberger, V. Atkinson, A. Hill, L. Fecher, M. Millward, P. Nathan, N. Khushalani, P. Queirolo, C. Ritchings, M. Lobo, M. Askelson, Hao Tang, S. Dolfi, P. Ascierto, J. Weber   +30 more
semanticscholar   +1 more source